Skip to content
Tallac Therapeutics, Inc
Tallac Therapeutics, Inc

News

Home
News
2021

2021

In Publication and DataPosted October 21, 2021

Tallac SITC 2021 Presentation

More
In Latest NewsPosted April 15, 2021

Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer

More
In Publication and DataPosted April 12, 2021

Tallac AACR 2021 Presentation

More
In Publication and DataPosted March 12, 2021

AACR 2021 presentation on preclinical data for TAC-001

More
In Latest NewsPosted March 4, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

More

Categories

  • Latest News (7)
  • Publication and Data (4)

Recent Posts

  • Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
  • Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
  • Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
  • Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
  • Tallac SITC 2021 Presentation

Archives

  • January 2023
  • November 2022
  • July 2022
  • May 2022
  • October 2021
  • April 2021
  • March 2021
  • December 2020
  • November 2020
Tallac Therapeutics, Inc
  • (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Linkedin-in Envelope

Copyright © 2020-2023 Tallac Therapeutics, Inc. All Rights Reserved.